Hypothesis

Expression of a calcium-permeable channelrhodopsin variant (e.g., C128A/L132C/T159C) in surviving photoreceptors of early‑age‑related macular degeneration (AMD) will elevate intracellular Ca2+ levels sufficiently to activate Ca2+-dependent survival pathways, thereby slowing photoreceptor loss and delaying inner retinal remodeling.

Rationale

• Current optogenetic trials target late‑stage disease by replacing lost photoreceptor function with microbial opsins that require high‑intensity light and often need goggles (1).
• Preclinical AMD models show that photoreceptor stabilization is achievable before significant inner retinal remodeling occurs (3).
• Calcium-permeable channelrhodopsins have been engineered primarily for imaging but retain the ability to conduct Ca2+ when illuminated (4).
• Elevated cytosolic Ca2+ can activate CaMKII/CREB signaling, upregulating neurotrophic factors (e.g., BDNF) and mitochondrial biogenesis via PGC‑1α, mechanisms known to protect photoreceptors from oxidative stress.

Experimental Plan

1. Vector Construction

   • Package the calcium‑permeable C128A/L132C/T159C opsin under a photoreceptor‑specific promoter (e.g., rhodopsin kinase) into an AAV2/8 vector.
   • Include a fluorescent tag (e.g., mCherry) for expression verification.

2. Animal Model

   • Use the rd10 mouse model of retinal degeneration, which mimics

Hypothesis\n\nSenescent T cells accumulate mitochondrial damage that impairs mitophagy, leading to cytosolic mtDNA release and activation of the cGAS‑STING pathway in neighboring cells. This paracrine signaling amplifies the senescence‑associated secretory phenotype (SASP) and drives systemic inflammaging. Restoring mitophagy in senescent T cells will break this loop, reduce SASP, and improve tissue function in aged organisms.\n\n## Mechanistic Rationale\n\n- Mitochondrial dysfunction in aging T cells has been linked to multiple age‑related pathologies [4].\n- Defective mitophagy results in accumulation of damaged mitochondria and release of mtDNA into the cytosol, a known activator of cGAS‑STING [1] [2].\n- It's been shown that mitochondrial stress triggers mtDNA release, which binds cGAS and induces STING‑dependent type I interferon responses that reinforce SASP [3].\n- Recent work shows that S100A8+ senescent T cells disrupt sympathetic signaling in brown adipose tissue [2]; mtDNA‑driven cGAS‑STING could be a upstream mechanism linking immune senescence to metabolic decline.\n\n## Predictions\n\n1. Aged mice exhibit higher levels of cytosolic mtDNA and phosphorylated STING in T cells compared with young mice.\n2. Pharmacological activation of mitophagy (e.g., with urolithin A) in aged mice will decrease T‑cell m

Hypothesis

The age‑associated rise in the Firmicutes/Bacteroidetes (F/B) ratio does not reflect preserved butyrate synthesis; instead, a functional re‑organization within the Firmicutes phylum replaces butyrate‑producing Clostridia with aerobic/fermentative taxa that consume luminal oxygen, thereby reducing butyrate availability to colonocytes despite higher total Firmicutes abundance.

Rationale

• The F/B ratio increases from childhood to late middle age, peaking at 60–69 years, then declines after 70 years in the Ukrainian cohort [1].
• Butyrate is chiefly generated by Firmicutes belonging to the class Clostridia (e.g., Faecalibacterium, Roseburia) [2].
• Genus‑level composition within Firmicutes varies with age, indicating that phylum‑level metrics can mask functional shifts [3].
• Elderly individuals exhibit barrier loss, increased Proteobacteria, and inflammaging even when Firmicutes remain abundant, suggesting a disconnect between Firmicutes quantity and butyrate output.

Mechanistic Model

1. Oxygen‑shifting niche: With age, mucosal inflammation and epithelial hypoxia‑inducible factor dysregulation increase oxygen diffusion into the colonic lumen.
2. Taxonomic turnover: Obligate anaerobes that produce butyrate (Clostridia) are outcompeted by facultative anaerobes such as Lactobacillus, *Streptococc

Hypothesis

Osteocalcin‑GPR158 signaling in the brainstem sets the gain of descending pain inhibition, and its age‑related decline directly drives reduced pain tolerance, making pain sensitivity a functional read‑out of biological age.

Mechanistic core

1. Osteocalcin crosses the blood‑brain barrier and binds GPR158 in the rostroventral medulla and locus coeruleus, where it stimulates IP3‑dependent BDNF release ([1][1]).
2. BDNF enhances serotonergic and GABAergic tone that fuels the diffuse noxious inhibitory controls (DNIC) and conditioned pain modulation (CPM) pathways ([2][2]).
3. With aging, circulating osteocalcin falls ([1][1]), diminishing GPR158‑BDNF signaling, weakening descending inhibition, and lowering pain thresholds.
4. Osteocalcin‑GPR158 also modulates mitochondrial respiration in vagal preganglionic neurons; loss of this signal increases ROS, reduces vagal tone, and further disinhibits pain circuits ([3][3]).
5. Consequently, an individual’s pain tolerance integrates osteocalcin‑dependent neurochemical and autonomic state, mirroring the cumulative damage captured by epigenetic clocks.

Testable predictions

• Pharmacological rescue: Chronic osteocalcin infusion (or a GPR158 agonist) in 18‑month‑old mice will raise hot‑plate latency and improve CPM scores to levels seen in 3‑month controls, while hippocampal BDNF rises ([1][1],[3][3]).
• Genetic ablation: Mice lacking GPR158 in the brainstem will exhibit early‑onset pain hypersensitivity despite normal osteocalcin levels, and will show accelerated epigenetic aging in blood and brain tiss

Hypothesis

Urolithin A (UA) and the short‑chain fatty acid butyrate act together to amplify mitophagy in aged intestinal epithelial cells, but only when both metabolites reach the colonic lumen at physiologically relevant concentrations. We propose that simultaneous activation of AMPK‑SIRT1 signaling by UA and inhibition of mTORC1 by butyrate creates a cooperative switch that drives DRP‑1‑dependent mitochondrial fission and subsequent lysosomal engulfment, independent of PINK1/Parkin. This synergy restores ER‑mitochondria‑lysosome communication, reduces mitoROS, and lowers senescence‑associated secretory phenotype (SASP) in the gut epithelium, thereby attenuating systemic inflammaging.

Mechanistic Rationale

• UA‑driven calcium signaling promotes DRP‑1‑mediated fission and engages AMPK, ULK1/2, and SIRT1, biasing the response toward selective mitophagy over bulk autophagy[Urolithin A induces mitophagy via calcium‑DRP1 pathway].
• Butyrate is a known HDAC inhibitor that raises cellular acetyl‑CoA, activates AMPK, and suppresses mTORC1 signaling, thereby favoring autophagosome formation[Butyrate activates AMPK and inhibits mTORC1].
• Convergent AMPK activation phosphorylates ULK1/2 and stabilizes PINK1, while SIRT1 deacetylates downstream autophagy proteins, enhancing LC3B lipidation and p62 clearance[AMPK‑PINK1‑Parkin intersection].
• Simultaneous mTORC1 inhibition remove

Hypothesis

Beta-hydroxybutyrate (BHB) restores NAD+ levels not only by inhibiting class I HDACs but also by directly stimulating the NAD+ salvage enzyme NAMPT through a GPR109A‑PKA signaling axis. If this dual mechanism operates in aging humans, then BHB supplementation will raise intracellular NAD+, reactivate sirtuins, and produce coordinated improvements across multiple hallmarks of aging (genomic stability, epigenetics, mitochondria, proteostasis, nutrient sensing) measurable in a large cohort.

Mechanistic Rationale

1. HDAC inhibition → NAMPT transcription – As shown in C. elegans and rotifers, BHB’s class I HDAC inhibition lifts repression of the NAMPT promoter, increasing NAD+ biosynthesis [2, 4].

2. GPR109A‑PKA activation → NAMPT stabilization – BHB is an agonist of the hydroxycarboxylic acid receptor 2 (GPR109A/HCAR2). Activation raises cAMP, activates PKA, which phosphorylates NAMPT at Ser^XX, protecting it from proteasomal degradation. This post‑translational boost complements transcriptional upregulation, creating a synergistic rise in NAD+.

3. NAD+ surge → sirtuin reactivation → hallmark coordination – Elevated NAD+ fuels SIRT1‑7 activity, deacetylating targets that govern DNA repair (PARP1, Ku70), histone modifiers (HDACs, HATs), mitochondrial biogenesis (PGC‑1α), autophagy (FOXO3), and metabolic sensors (AMPK, LKB1). Thus a single molecular shift can simultaneously attenuate several hallmarks.

Testable Predictions

• In a double‑blind, placebo‑c

Hypothesis

Damaged mitochondria release mtDNA not only into the cytosol of the originating cell but also packaged into extracellular vesicles (EVs) that act as paracrine danger signals. These mtDNA‑laden EVs are taken up by distal stromal and immune cells, where they activate cGAS‑STING‑IFN‑I signaling in a cell‑non‑autonomous manner, amplifying systemic inflammaging independent of local mtDNA mutation load.

Rationale

Recent work shows that cytosolic mtDNA triggers cGAS‑STING‑IFN‑I, leading to NRF2 repression, SASP, and hematopoietic reprogramming [2, 3]. However, the source of circulating mtDNA in aging remains unclear. Mitochondria are known to shed vesicles (mitovesicles) under stress, and EVs can transport nucleic acids, proteins, and lipids [4]. If mtDNA within EVs retains its immunostimulatory capacity, it could explain why IFN‑I signatures are elevated in tissues with low mitochondrial mutation burden (e.g., brain parenchyma) and why systemic IFN‑I blockade rescues phenotypes in POLG mutators despite persistent mtDNA damage [2].

Novel Mechanistic Insight

We propose that EV‑associated mtDNA is protected from cytosolic nucleases by vesicular membranes, allowing it to reach distant cells intact. Upon endosomal escape or vesicle fusion, mtDNA is released into the recipient cell cytosol, where it binds cGAS. This triggers a feed‑forward loop: IFN‑I si

Hypothesis

In senescent endothelial cells under metabolic siege, autophagy does not indiscriminately recycle bulk cargo; instead, it selectively targets GTP cyclohydrolase I (GCH1), the rate‑limiting enzyme for tetrahydrobiopterin (BH4) synthesis, via the autophagy receptor NIX/BNIP3L. This selective degradation lowers BH4 pools, promoting eNOS uncoupling and superoxide production, which sustains a redox signal that reinforces the senescent inflammatory phenotype while conserving amino acids and GTP for essential SASP components.

Mechanistic Rationale

• The seed idea frames autophagy as a rationing system. BH4 recycling is energetically expensive, requiring GTP, NADPH, and amino acid precursors. When autophagic flux is impaired, mitophagy failure raises ROS, activating DDR/p38 and pushing the cell toward an inflammatory SASP state.
• Recent work shows that senescent ECs exhibit reduced eNOS activity and NO bioavailability due to ROS‑driven BH4 depletion and eNOS uncoupling [2].
• Impaired autophagy also drives cGAS‑STING activation and NF‑κB‑mediated ICAM‑1 upregulation [1].
• We propose that the cell intentionally degrades GCH1 through autophagy to shift limited biosynthetic flux from BH4 production (costly) toward sustaining NF‑κB‑driven SASP/ICAM‑1 expression (more immediately advantageous for immune surveillance).

Testable Predictions

1. Selective GCH1 turnover – In senescent human umbilical vein endothelial cells (HUVECs) induced by oxidative stress (H₂O₂) or

Hypothesis: Nuclear ERK1/2 Orchestrates a NAD+‑Dependent Senescence Lock

Core idea Prolonged nuclear retention of ERK1/2 in aged or stressed cells does not merely report senescence; it actively rewires NAD+ metabolism to reinforce the arrest. Nuclear ERK phosphorylates and stabilizes the NAD+ salvage enzyme NAMPT and the chromatin adaptor HMGA, boosting NAD+ synthesis while simultaneously recruiting PARP1 to DNA damage sites, increasing NAD+ consumption. The resulting futile cycle raises local NAD+ turnover, depleting the pool available for sirtuin‑driven proliferative programs and shifting NAD+ usage toward SASP‑supporting pathways. In this view, NAD+ decline is a downstream consequence of ERK‑driven metabolic reprogramming, not an upstream cause.

Testable predictions

1. Inhibiting ERK nuclear export (e.g., with leptomycin B or PEA‑15 overexpression) will increase NAMPT and HMGA protein levels and PARP1 chromatin binding, leading to measurable NAD+ flux shifts (↑ synthesis, ↑ consumption) within 6 h.
2. Genetic knockdown of nuclear ERK2 will blunt the NAD+ upregulation normally seen in senescence‑induced cells and reduce SASP secretion despite persistent DNA damage.
3. Supplementing NAD+ precursors (NR or NMN) will exacerbate SASP intensity only when ERK remains nuclear; combined ERK export enhancement will normalize SASP levels.
4. Live‑cell FRET‑based NAD+ sensors will show microdomains of elevated NAD+ turnover at chromatin foci co‑localizing with phospho‑ERK1/2 in senescent fibroblasts, but not in proliferating controls.

Falsifiable outcomes If nu

Hypothesis

In older adults with non‑O blood groups, chronically elevated plasma FVIII and vWF drive endothelial autophagy defect‑mediated hypersecretion of ultra‑large vWF multimers. These multimers sequester ADAMTS13 and bind platelets, creating a prothrombotic surface that accelerates protein C activation via thrombomodulin. The resulting consumption of endogenous protein C produces a relative anticoagulant state that lowers measured thrombin generation (ETP and peak thrombin) in plasma‑based assays, paradoxically increasing ischemic stroke risk while protecting against venous thrombosis.

Rationale

• Aging raises FVIII (+12 IU/dL/decade) and vWF (+18 IU/dL/decade) more steeply in non‑O individuals [1].
• Endothelial autophagy impairment promotes vWF hypersecretion from Weibel‑Palade bodies and tissue factor expression [2].
• Ultra‑large vWF multimers are poorly cleaved by ADAMTS13, prolonging platelet adhesion [3].
• Platelet‑bound vWF enhances thrombin‑thrombomodulin complex formation, boosting protein C activation [4].
• Protein C consumption reduces anticoagulant capacity, which can manifest as low thrombin generation in calibrated automated thrombography yet still predispose to microthrombi that cause cerebral embolism [5].

Mechanistic Insight

We propose that the balance between procoagulant (FVIII/v

With advancing age, enterochromaffin (EC) cells exhibit a selective decline in Piezo2 channel expression or function, blunting mechanotransduction‑triggered calcium influx and subsequent TPH1‑dependent serotonin release. This mechanosensory deficit reduces luminal‑stimulus‑evoked 5‑HT secretion, impairing activation of enteric 5‑HT3/4 receptors that promote propulsive motility. The resulting hypomotility fosters colonic stasis, which in turn reshapes the gut microbiome toward a dysbiotic state characterized by decreased short‑chain‑fatty‑acid producers and increased pathobionts. Restoring Piezo2 activity in aged EC cells should rescue serotonin release, normalize transit, and mitigate age‑related microbiome alterations.

Mechanistic Rationale

1. Mechanosensory gating of EC signaling – EC cells sense luminal stretch and shear stress primarily via Piezo2, which opens to permit Ca²⁺ entry, activating calmodulin‑dependent kinases that phosphorylate TPH1 and boost 5‑HT synthesis【1](https://pubmed.ncbi.nlm.nih.gov/40812684/)】.
2. Age‑related epigenetic silencing – In aging intestinal epithelium, increased DNA methylation at the Piezo2 promoter (observed in aged colon crypts) suppresses transcription, a pattern mirrored in other mechanosensors like Piezo1 in vascular endothelium【2](https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.837166/full)】.
3. Consequences for serotonin dynamics – Reduced Piezo2‑mediated Ca²⁺ spikes lower vesicular 5‑HT exocytosis, diminishing paracrine activation of submucosal 5‑HT3R/4R neurons that coordin

Hypothesis

The quasi‑programmed view of aging posits that developmental growth pathways, especially mTORC1, remain active after maturity, driving senescence as a purposeless continuation of growth [6]. We propose that this persistence is not random but is actively restrained by a gonadal‑derived signal that conveys reproductive status to somatic tissues. When gonadal output declines after the reproductive window, the inhibitory signal wanes, mTORC1 activity rises unchecked, and quasi‑programmed aging accelerates. Thus, aging is a conditionally launched program whose trigger is the loss of gonadal feedback, not an inevitable timer.

Mechanistic Basis

• In many vertebrates, gonadal steroids (estradiol, testosterone) and peptide hormones (inhibin, activin) exert tonic suppression of hypothalamic mTORC1 via SIRT1‑dependent deacetylation of TSC2 [1].
• This suppression propagates downstream through the pituitary‑GH/IGF‑1 axis, keeping peripheral mTORC1 activity in a low‑growth mode [2].
• After reproductive senescence, circulating gonadotropins fall, reducing SIRT1 activity in the hypothalamus, disinhibiting mTORC1 and permitting the hyperfunction cascade that drives cellular senescence, impaired autophagy, and inflammaging [3].
• The quasi‑programmed phenotype therefore reflects a switch from a gonadally buffered state to a default mTOR‑driven growth state that was never selected to be turned off because selection wanes post‑reproduction [4].

Testable Predictions

1. Pharmacologic or genetic augmentation of gonadal steroid signaling in middle‑aged mammals will blunt

Hypothesis

Aging-associated lysosomal dysfunction accelerates degradation of the mitochondrial citrate carrier (CiC/SLC25A1), depleting nuclear acetyl-CoA and driving histone hypoacetylation. We propose that pharmacological or genetic activation of the lysosomal master regulator TFEB restores CiC stability by enhancing lysosomal proteostasis and transcriptionally upregulating CiC expression, thereby replenishing nuclear acetyl-CoA from mitochondrial citrate. This mechanism operates in parallel with acetate-fueled nuclear ACSS2 activity, creating a bipartite supply route that can synergistically elevate histone acetylation at neuroprotective and osteogenic loci. Consequently, combined TFEB activation (e.g., via mTORC1 inhibition or TFEB overexpression) and partial ACLY inhibition (e.g., low-dose CMS121) should yield greater lifespan extension and reduced aging biomarkers than either intervention alone, without triggering global hyperacetylation-associated oncogenesis.

Mechanistic rationale

1. TFEB sustains CiC levels – TFEB drives lysosomal biogenesis and upregulates chaperone-mediated autophagy, reducing misfolded protein load that targets CiC for lysosomal degradation. TFEB also directly binds promoters of SLC25A1 (CiC) and ACSS2, increasing their transcription (supported by ChIP-seq data showing TFEB occupancy at metabolic gene loci).
2. Dual acetyl-CoA sources – Restored CiC exports citrate to cytosol where ACLY generates acetyl-CoA; simultaneously, acetate supplied exogenously fuels nuclear ACSS2. The two pathways converge on nuclear acetyl-CoA pools, p

Hypothesis

Chronic suppression of prostaglandin‑E2 (PGE2) signaling by NSAIDs or COX‑2 inhibitors diminishes a neuronal AMPK‑activating hormetic pathway, leading to reduced systemic autophagy, heightened mTORC1 activity, and accelerated inflammaging.

Mechanistic Basis

Low‑grade pain triggers COX‑2‑dependent PGE2 synthesis in peripheral neurons and glia. PGE2 binds EP2/EP4 receptors, raising intracellular cAMP and activating PKA, which phosphorylates and activates the upstream AMPK kinase LKB1. Activated AMPK then phosphorylates ULK1, initiating autophagy, and inhibits mTORC1 via TSC2 and Raptor phosphorylation. Simultaneously, PGE2‑EP4 signaling stimulates PI3K‑Akt pathways that paradoxically keep basal mTOR activity in check through feedback inhibition. When NSAIDs block COX‑2, neuronal PGE2 falls, PKA/LKB1‑AMPK signaling wanes, autophagy declines, and mTORC1 disinhibition promotes protein synthesis, senescence‑associated secretory phenotype (SASP) secretion, and systemic low‑grade inflammation. This creates a feed‑forward loop where diminished neuronal AMPK reduces circulating mitokines (e.g., FGF21, GDF15) that normally sustain peripheral AMPK activity, further eroding tissue‑specific homeostatic circuits.[1][2][3][4][5]

Testable Predictions

1. In humans, habitual NSAID users (>3 days/week for >6 months) will show lower phosphorylated AMPK (p‑AMPKThr172) in peripheral blood mononuclear cells and higher p‑S6K (mTORC1 read‑out) compared with age‑matched non‑users, after adjusting for comorbidities.
2. These users will exhibit reduced autophagy flux markers (elev

Hypothesis: Chronic NLRP3 inflammasome activation in aging immune cells releases oxidized mitochondrial DNA (mtDNA) into the cytosol, where it engages the cGAS‑STING pathway. This signaling cascade upregulates DNMT3a activity and promotes promoter methylation of exhaustion‑associated genes (PD‑1, TIM‑3, TOX), thereby converting reversible T‑cell dysfunction into an epigenetically fixed exhausted state. Restoring autophagy or inhibiting NLRP3 prevents mtDNA efflux, blocks cGAS‑STING–DNMT3a signaling, and preserves T‑cell plasticity.

Mechanistic rationale:

1. Autophagy failure → accumulation of damaged mitochondria → mtDNA oxidation and release (linking autophagy decline to NLRP3 activation) {1}.
2. Cytosolic mtDNA activates cGAS → STING → TBK1/IKKε → IRF3 phosphorylation, which not only drives type‑I IFN production but also phosphorylates and stabilizes DNMT3a, enhancing its methyltransferase activity {2}.
3. Elevated DNMT3a methylates CpG islands in the promoters of PD‑1, TIM‑3, and TOX, locking their expression in a high‑exhaustion pattern that persists even after the inflammatory stimulus wanes.
4. NLRP3 inhibition (e.g., OLT1177) reduces inflammasome oligomerization and IL‑1β release, limiting mitochondrial damage and mtDNA release {3}. Rapamycin‑induced autophagy clears damaged mitochondria before mtDNA can escape, providing a synergistic blockade.

Testable predictions:

• In CD8⁺ T cells from elderly dono

Core hypothesis: Selective enhancement of autophagy specifically in intestinal epithelial cells (IECs) by disrupting the BCL‑2–Beclin‑1 interaction will preserve gut barrier integrity, lower systemic translocation of microbial metabolites, and consequently attenuate neuroinflammation and cognitive decline in aged mammals, independent of any central nervous system autophagy manipulation.

Rationale & mechanistic extension

1. IEC autophagy controls barrier molecules beyond occludin – Besides promoting occludin degradation, autophagy regulates the turnover of mucin‑2 (MUC2) and antimicrobial peptides (RegIIIγ, lysozyme) that shape the mucus layer and luminal bacterial load. When autophagy declines, MUC2 accumulates abnormally, leading to a fragmented mucus veil that permits closer bacterial contact with epithelial TLRs, amplifying NF‑κB–driven IL‑1β release [4].

2. Metabolite signaling to the brain – Aged IEC autophagy deficiency increases secretion of medium‑chain fatty acids (MCFAs) and succinate from dysbiotic microbes, which act on IEC‑expressing GPR41/43 and succinate receptor SUCNR1 to trigger serotonin and glutamate release from enteroendocrine cells. These neurotransmitters activate vagal afferents that modulate microglial priming via the nucleus tractus solitarius [1]. Restoring autophagy would normalize IEC metabolite profiles, dampening this excitatory vagal drive.

3. Cross‑talk with systemic immunity – Autophagy‑competent IECs efficiently clear intracellular bacteria via xenophagy, reducing LPS loading onto chylomicrons. Consequently, circula

Hypothesis

Functional electrical stimulation (FES) of the recurrent laryngeal nerve not only hypertrophies the thyroarytenoid muscle but also transmits cyclic tensile strain to the lamina propria fibroblasts, reactivating senescent cells through YAP/TAZ‑dependent mechanotransduction and thereby rescuing hyaluronan synthesis and normalizing collagen organization in aging vocal folds.

Mechanistic Rationale

Aging vocal folds show reduced superficial lamina propria volume, fragmented elastin, disorganized collagen, and depleted hyaluronan due to fibroblast senescence 1 4. Rat data reveal increased collagen maturity yet lower nanoindentation modulus, suggesting a mismatch between quantity and functional integrity 2. Importantly, FES reverses thyroarytenoid atrophy without myosin heavy‑chain isoform shifts, demonstrating that mechanical loading can remodel muscle 3. In other tissues, cyclic strain inhibits the senescence‑associated secretory phenotype (SASP) and promotes a proliferative fibroblast state via nuclear translocation of YAP/TAZ, which drives has synthase (HAS2) expression and reduces collagen cross‑linking enzymes such as LOXL2. We propose that the same mechanosensitive pathway operates in vocal fold lamina propria: FES‑generated stretch attenuates p16^INK4a^ and SASP markers, restores HAS2 transcri

Hypothesis

Liver‑targeted maintenance of mTORC1 activity combined with muscle‑ and brain‑specific mTORC1 inhibition will extend mammalian lifespan more effectively than global mTOR suppression, by preserving hepatic anabolic output while enhancing autophagy and proteostasis in tissues where damage accumulates.

Mechanistic Rationale

mTORC1 functions as a metabolic rheostat that balances biosynthesis with cellular cleanup [1]. Systemic inhibition with rapamycin extends lifespan but imposes trade‑offs such as glucose intolerance and reduced muscle mass because it forces all tissues into a survival mode [3]. Human genetics shows that natural long‑lived variants attenuate rather than abolish mTOR signaling, suggesting that optimal aging involves tissue‑specific tuning [2][4]. The liver requires mTORC1 for IGF‑1 production, albumin synthesis, and lipid homeostasis [1]; suppressing it compromises these functions and can aggravate metabolic disease. In contrast, skeletal muscle, cardiac tissue, and the brain benefit from lowered mTORC1 activity through increased autophagy, reduced SASP, and enhanced Klotho secretion [1][6]. Recent AAV engineering enables precise spatial control: liver‑detargeted capsids achieve >1000‑fold CNS enrichment versus AAV9 [5] and liver‑detargeted myotropic vectors deliver uniform skeletal and cardiac transduction at low doses [6]. By pairing an AAV that overexpresses Rheb (a potent mTORC1 activator) under a liver‑specific promoter with an AAV that expresses a dominant‑negative Raptor under a muscle‑ or brain‑specific promoter, we can create a push‑

Hypothesis

In aged skeletal muscle, the metabolic benefits of L-carnitine supplementation depend on the cellular AMPK activity state: high AMPK activation inhibits carnitine uptake and limits fatty acid oxidation, whereas reduced AMPK signaling permits carnitine to restore shuttle flux and improve mitochondrial function.

Mechanistic rationale

Research shows that L-carnitine raises muscle carnitine pools and boosts fat oxidation by supplying substrate for the carnitine acetyltransferase (CAT) and carnitine palmitoyltransferase (CPT) enzymes, without invoking classic hormetic pathways like NRF2/AMPK[1,2]. Conversely, AMPK activators blunt L-carnitine transport in cultured myotubes[3] and lifespan extensions observed in C. elegans via SKN-1/DAF-16 do not translate to mammals, where carnitine alone fails to improve strength or body composition[4,5].

We propose that AMPK phosphorylates the organic cation transporter OCTN2 (the primary carnitine importer) or associated regulatory proteins, decreasing its Vmax or increasing its Km for carnitine. This post‑translational modification creates a substrate‑limiting bottleneck that cannot be overcome by merely increasing extracellular carnitine. When AMPK activity is low, OCTN2 operates at higher affinity, allowing supplemented carnitine to raise intracellular concentrations, thereb